Pfizer, Teva Settle Patent Litigation on Viagra
Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.
Pfizer has settled its litigation against Teva Pharmaceuticals USA Inc., relating to Pfizer’s patent covering the use of Pfizer's Viagra (sildenafil citrate) to treat erectile dysfunction in 25-, 50-, and 100-mg tablets. The patent expires in April 2020, including pediatric exclusivity. As a result of the settlement, Teva will be allowed to launch a generic version of Viagra under a royalty-bearing license on Dec. 11, 2017, in the United States on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential. Teva has received tentative approval from FDA for its generic version of Viagra.
Sources: Pfizer and Teva Pharmaceuticals
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
